Company intelligence / Profile preview

Pharma Equity Group

Hørsholm, Denmarkpharmaequitygroup.com ↗

Ownership: Public · PEG
Development stage: Other

Overview

The company’s main subsidiary, Reponex Pharmaceuticals, has multiple candidates in Phase II clinical trials targeting serious inflammatory diseases and colorectal cancer. No commercial products yet; all programs are in the clinical development phase.

Therapeutic areas: DermatologyGastroenterologyOncologyInfectious Diseases
Modalities: Small moleculeDrug delivery system
Industry: Biotech

Partnerships

Collaborations with academic institutions and research organizations are mentioned but not named specifically. Strategic partnerships sought for late-stage/commercialization phases.

Financials

Market cap: $36.2B
Total revenue: $2.6B
Enterprise value: $60.7B

Beyond the preview

Go deeper on Pharma Equity Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharma Equity Group.

Explore the full profile